Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← All stories
IndustryJune 8, 2026

Health Economist Calls for New Payment Infrastructure for Gene Therapies

Health economist William Padula argues that high-cost gene therapies, including treatments costing $2 million or more, require new financing models to enable patient access. The commentary asserts that the barrier to deploying curative therapies is not scientific but financial and infrastructural. Padula contends that existing payment systems are ill-equipped to handle the upfront costs of one-time curative treatments. The piece calls for innovative financing mechanisms to bridge the gap between therapeutic breakthroughs and patient access.

Why it mattersMedicaid managed care organizations face growing pressure to cover costly gene therapies while managing capitated budgets, making alternative payment models and risk-sharing arrangements operationally critical.

Pharmacy · Managed Care · Finance

Read the full article at statnews.com →
Share this briefing

You might also like

← All stories

Get the daily briefing.